This study was approved by the Institutional Review Board of Fox Chase Cancer Center. Paraffin-embedded tissue sections, 4 μm, were used for immunohistochemical analysis; 10 μm sections were used for ...

A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.

April 26, 2012 — The US Food and Drug Administration (FDA) has approved everolimus (Afinitor, Novartis) for the treatment of renal angiomyolipomas not requiring immediate surgery in patients with ...

January 10, 2008 — Year-long treatment with the immunosuppressive drug sirolimus led to shrinkage of angiomyolipoma tumors, with volume reduced by nearly 50%, along with improvement in lung function ...

Within 4 months after the start of treatment for angiomyolipomas, tumor volume had shrunk by at least 25% in 10 of 18 evaluable patients. By 6 months, 10 of 14 patients had at least a 25% decrease in ...

68Ga-FAPI-46 PET/CT for cancer imaging: Results of a single-center, prospective, interventional, single-arm clinical trial. Demographic and clinical characteristics of patients with renal AML: ...

Background A 17-year-old girl, who was diagnosed with tuberous sclerosis in infancy, presented with multiple bilateral renal masses, the largest of which was 6.0 cm in diameter on the left side.

Researchers have shown that the immunosuppressant everolimus provides a potential new treatment option for patients with tuberous sclerosis and associated angiomyolipomas. In a randomized, phase III ...

TSC-Related Pediatric Renal Tumors Respond to Everolimus Drug found to benefit children with renal angiomyolipomas associated with tuberous sclerosis complex. AMSTERDAM—Everolimus appears to ...